D Sachdev

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Targeting the type I insulin-like growth factor system for breast cancer therapy
    Deepali Sachdev
    Departments of Medicine and Pharmacology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Curr Drug Targets 11:1121-32. 2010
  2. ncbi The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival
    D Sachdev
    Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Oncogene 29:251-62. 2010
  3. ncbi Regulation of breast cancer metastasis by IGF signaling
    Deepali Sachdev
    Department of Medicine and Masonic Cancer Center, University of Minnesota, MMC 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    J Mammary Gland Biol Neoplasia 13:431-41. 2008
  4. ncbi Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer
    Deepali Sachdev
    Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, MMC 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Curr Opin Mol Ther 9:299-304. 2007
  5. ncbi Disrupting insulin-like growth factor signaling as a potential cancer therapy
    Deepali Sachdev
    University of Minnesota Cancer Center, MMC 806, 420 Delaware Street Southeast, Minneapolis, MN 55455, USA
    Mol Cancer Ther 6:1-12. 2007
  6. ncbi Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer
    Deepali Sachdev
    Department of Medicine and Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware St, SE, Minneapolis, MN 55455, USA
    J Mammary Gland Biol Neoplasia 11:27-39. 2006
  7. ncbi Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer
    Deepali Sachdev
    University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Cancer Res 66:2391-402. 2006
  8. ncbi Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation
    H Zhang
    Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Oncogene 29:2517-27. 2010
  9. ncbi A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I
    Deepali Sachdev
    Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Cancer Res 63:627-35. 2003
  10. ncbi New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation
    Adrian V Lee
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 9:516S-23S. 2003

Detail Information

Publications16

  1. ncbi Targeting the type I insulin-like growth factor system for breast cancer therapy
    Deepali Sachdev
    Departments of Medicine and Pharmacology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Curr Drug Targets 11:1121-32. 2010
    ..This article reviews the different drugs against IGF-1R that are being tested in and how this receptor pathway can be optimally targeted for cancer therapy with an emphasis on breast cancer therapy...
  2. ncbi The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival
    D Sachdev
    Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Oncogene 29:251-62. 2010
    ..The multiple phenotypes regulated by IGF1R must be considered during development of this therapeutic strategy as inhibition of metastasis independent of inhibition of tumor growth is not easily assessed in phase II clinical trials...
  3. ncbi Regulation of breast cancer metastasis by IGF signaling
    Deepali Sachdev
    Department of Medicine and Masonic Cancer Center, University of Minnesota, MMC 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    J Mammary Gland Biol Neoplasia 13:431-41. 2008
    ....
  4. ncbi Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer
    Deepali Sachdev
    Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, MMC 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Curr Opin Mol Ther 9:299-304. 2007
    ..CP-751871 in combination with docetaxel and prednisone in patients with hormone-refractory prostate cancer, and a phase II trial of CP-751871 in combination with exemestane in hormone receptor positive advanced breast cancer [corrected]..
  5. ncbi Disrupting insulin-like growth factor signaling as a potential cancer therapy
    Deepali Sachdev
    University of Minnesota Cancer Center, MMC 806, 420 Delaware Street Southeast, Minneapolis, MN 55455, USA
    Mol Cancer Ther 6:1-12. 2007
    ....
  6. ncbi Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer
    Deepali Sachdev
    Department of Medicine and Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware St, SE, Minneapolis, MN 55455, USA
    J Mammary Gland Biol Neoplasia 11:27-39. 2006
    ..Several reagents disrupting IGF signaling have been developed and clinical trials validating IGF signaling as a target in cancer therapy are underway. This review highlights the approaches to inhibiting IGF signaling in breast cancer...
  7. ncbi Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer
    Deepali Sachdev
    University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Cancer Res 66:2391-402. 2006
    ..Thus, antibodies against IGF1R provide inhibition of both IGF and insulin signaling in cancer cells...
  8. ncbi Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation
    H Zhang
    Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Oncogene 29:2517-27. 2010
    ..In conclusion, downregulation of IR inhibited cancer cell proliferation, angiogenesis, lymphangiogenesis and metastasis. Our data argue that IR should also be targeted in cancer therapy...
  9. ncbi A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I
    Deepali Sachdev
    Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Cancer Res 63:627-35. 2003
    ..These results indicate that such chimeric single-chain antibodies against IGF1R have future potential in breast cancer therapy by causing down-regulation of receptor...
  10. ncbi New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation
    Adrian V Lee
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 9:516S-23S. 2003
    ..This review will highlight how recent studies using these STIs have elucidated novel mechanisms of STI action that may be used in the development of new therapeutic strategies for the treatment of cancer...
  11. ncbi A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma
    Seunguk Oh
    Masonic Cancer Center, Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 15:6137-47. 2009
    ..Our purpose was to reduce toxin immunogenicity using mutagenesis, measure the ability of mutated drug to elicit B-cell antitoxin antibody responses, and show that mutated drug was effective against systemic breast cancer in vivo...
  12. ncbi Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo
    Xianke Zeng
    Department of Pharmacology and Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 15:2840-9. 2009
    ..The aim of this study was to determine the optimal sequence of combining anti-type I insulin-like growth factor receptor (IGF1R) antibodies with chemotherapeutic drugs in cancer cells in vitro and in vivo...
  13. ncbi Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells
    Hua Zhang
    University of Minnesota Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Breast Cancer Res Treat 114:277-85. 2009
    ..In addition, the inhibitory effect of AVE-1642 Qdots to cell proliferation implies that it may serve as a traceable therapeutic agent...
  14. ncbi A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells
    Deepali Sachdev
    Department of Medicine and Cancer Center, University of Minnesota, Minnesota 55455, USA
    J Biol Chem 279:5017-24. 2004
    ..Our data show that IGF1R can regulate several aspects of the malignant phenotype. In these cells, metastasis but not proliferation requires IGF1R function...
  15. ncbi The IGF system and breast cancer
    D Sachdev
    Department of Medicine, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Endocr Relat Cancer 8:197-209. 2001
    ....
  16. ncbi Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression
    Xihong Zhang
    Department of Medicine, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Breast Cancer Res Treat 83:161-70. 2004
    ..IRS-2 activation and integrin occupancy are both required for IGF-stimulated motility...